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Drug idiosyncrasy is an adverse event of unknown etiology that
occurs in a small fraction of people taking a drug. The histamine-
2 (H2)-receptor antagonist ranitidine causes idiosyncratic reactions
in patients. To investigate the hypothesis that ranitidine could
induce hematological toxic effects, the drug was administered
intraperitoneally (ip) to two of six groups of 200-220 g male Wistar
rats (n=6). Group I received as single dose of saline solution (NaCl,
200 µL) Group II received 200 µL of NaCl, ip, at 0, 24, 48 and
72 h, Group III (controls of the vehicle) received as single dose of
dimethyl sulfoxide (DMSO, 200μL), ip, Group IV (controls of the
vehicle) received 200 μL of DMSO, ip, at 0, 24, 48, and 72 h,
Group V received a single dose of 100 mg/kg of ranitidine in 200 μL
of DMSO) ip, Group VI received 50 mg/kg of ranitidine, in 200 μL
of DMSO, ip, at 0, 24, 48, and 72 h. Erythrograms, leucograms
were measured; percent methemoglobin content of the blood was
analyzed spectophotometrically. Methemoglobinemia increased to
a significant extent following ranitidine treatment, in both study
groups. White blood cell and neutrophil counts showed a discrete
reduction following either regime of treatment. A marginal
mobilization of the neutrophil pool probably occured. Following
the multiple dose regime, leukocyte counts increased, but their
distribution maintenance profile remained the same. The
administration of ranitidine to rats induces methemoglobinemia
in the administered doses, suggesting that from a certain
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Adverse drug reactions of unknown etiology that
occur in a small fraction of the treated population are
defined as idiosyncratic. These reactions are typically
unpredictable, show no obvious relation to dose, and
display a variable time to onset in relation to start of drug
therapy. Idiosyncratic reactions cause not only human
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suffering but also sometimes result in curtailing use of
otherwise effective therapeutic agents (Luyendyk et al.,
2003).
Idiosyncratic drug responses are commonly thought to
arise either from drug metabolism polymorphism or from an
allergic response to a drug or its metabolite(s). However, for
the majority of drugs, supporting evidence for either of these
hypotheses is lacking (Luyendyk et al., 2003).
Histamine H
2
-receptor antagonists are widely used
in the treatment of gastrointestinal diseases related to
gastric acid hypersecretion and cytoprotective effects
(Penston, Wormsley, 1986; Aymard et al., 1988; Munoz-
Arrebola et al., 1989). Ranitidine, one of such antagonists
was first marketed in 1981; since then, many patients have
been treated with this drug, and much experience
regarding its safety has been gathered (Vial et al., 1991).
A wide array of ranitidine side effects of infrequent
incidence has been reported; among them, are several ca-
ses of mixed hepatitis of which very few have been well-
documented. Ranitidine-associated acute hepatitis has been
estimated to occur in less than 1 per 100,000 patients
(Penston, Wormsley, 1986). Following long-term treatment
of prepyloric or duodenal ulcer with 2 x 150 mg of ranitidine
daily, a total of 6 adverse effects were observed in 5
(18.7%) out of 32 patients (Meryn et al., 1983).
Mikawa et al. (1999), found that while cimetidine







by neutrophils, in a dose-dependent manner, ranitidine
failed to do so, and did not appear to have any deleterious
effect on neutrophil function, an important consideration for
its use in severely ill patients.
In a study using Sprague-Dawley rats, ranitidine was
administered orally at doses of 30, 100, 300 and 1000 mg/kg.
Animals surviving this dose, presented increased salivation,
decreased body weight gain, increased water consumption,
increased urinary Na and K excretion, as well as increased
serum albumin content and increased liver, kidney and
heart weights (Takeuchi et al., 1983).
A case of leukocytosis and eosinophilia has been
reported by Gelwan et al. (1986), in a patient receiving
ranitidine therapy.
Nakada et al. (1996) concluded that acute renal failure
is one of the risk factors of ranitidine neurotoxicity, and that
increased sensitivity of the central nervous system to the drug
may contribute towards its toxicity in renal failure.
Luyendyk et al. (2003) in co-treatment of rats with
LPS and ranitidine resulted in the expected hepatocellular
damage as marked by increases in serum ALT and AST
activities and cholestatic injury as increases in serum GGT
activity, likely to cause idiosyncratic reactions.
In view of the various reports on adverse effects of
ranitidine, we decided to test the drug at respectively single
and multiple dose regimes, for effects on hematological




Ranitidine was administered intraperitoneally (ip) to
six groups of 6 animals each, of 200-220 g male Wistar rats
(n=6). Group I received a single dose of saline solution
(NaCl, 200 µL) Group II received 200 µL of NaCl, ip, at 0,
24, 48 and 72 h, Group III (controls of the vehicle) received
as single dose of dimethyl sulfoxide (DMSO, 200 µL), ip,
Group IV (controls of the vehicle) received 200 µL of
DMSO, ip, at 0, 24, 48, and 72 h, Group V received a single
dose of 100 mg/kg of ranitidine (Glaxo-Wellcome, S.Paulo,
Brazil) in 200 µL of DMSO) ip, Group VI received 50 mg/kg
of ranitidine, in 200 µL of DMSO, ip, at 0, 24, 48, and 72 h.
Two hours following treatment, animals were anesthetized
with ethyl ether, and blood was collected from the aorta,
and used for the determination of hematological
parameters and methemoglobinemia.
Analytical procedures
Hematological measurements included: manual red
cell and leukocyte counts (in Neubauer hemocytometer),
hematocrit (microhematocrit method), hemoglobin
(cyanomethemoglobin method), calculations of red indices,
differential leukocyte count (in blood smears stained with
Leishman) and reticulocyte count (with the supravital dye
brilhant crezyl blue) (Coates, 1995).
All blood samples were assayed for methemoglobin
levels relative to hemoglobin levels, by the spectro-
photometer technique of Grossman and Jollow (1988) and
Coleman et al. (1991).
Statistical analyses
Data were analyzed by ANOVA and by multiple
post-test comparisons according to Tukey-Kramer, using
the GraphPad Instat and Statgraphics software, the level
of significance being set at <0.05.
RESULTS
No significant differences were observed when we
compare the groups that received saline solution (NaCl) in
single doses and multiple doses with the groups that
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received DMSO (Table I). We compare then the animals
that received DMSO and those that received the drugs.
Within 2 hours following the administration of a single dose
of 100 mg/kg or of 50 mg/kg in multiple doses of ranitidine,
rapid, acute methemoglobinemia resulted, showing values
of 5.80 ± 0.84% and 6.50 ± 0.84%, respectively compared
to control values of 1.19 ± 0.21 and 4.22 ± 0.80%,
respectively (Table I). Methemoglobin levels increased
significantly after administration of either concentration,
suggesting a dose-dependent methemoglobinemic toxic
effect of ranitidine (Figure 1).
However, no significant differences in hematological
parameters of the red or white cell series was observed in
the groups studied (Tables I and II, respectively).
DISCUSSION
Ranitidine is a H
2
-receptor antagonist that has been
in use for the treatment of gastrointestinal diseases for
over a decade, thanks to the lack of serious adverse
reactions and a long required dosage interval (Fischer,
Counteur, 2001).
 Adverse reactions to drugs can be divided into two
categories. The first occurs when the reaction bears no
relation to the mode of action of the drug and occurs well
within the intended dosage range. This type of reaction is
often termed idiosyncratic, idiopathic or hypersensitivity.
A widely used drug associated with idiosyncratic
hepatotoxicity is the histamine –2 (H2)-receptor antagonist
ranitidine (Luyendyk et al., 2003).
Lewis (1987) after having given ranitidine to tens of
millions of patients, reported that its hepatic toxicity
supports such a low incidence, and that ranitidine-induced
hepatic injury is presumably due to hypersensitivity. Few
clinical reports implicate ranitidine as the cause of a
predominately cholestatic hepatitis, which resembles
ascending cholangitis, by predominantly presenting fever
and rigors. Eosinophil infiltration in the liver and a response
to rechallenge in some cases, suggest an immunological
mechanism for its pathogenesis. A direct toxic action is also
probable: H
2
 –blockers are toxic to isolated hepatocytes in
vitro, and also inhibit bile flow. Granulatomatous infiltration
of the liver has been shown to be evoked by a number of
drugs, including ranitidine. This effect sometimes occurs
TABLE I - Comparison of hematological parameters (red series) for ranitidine 100 mg/kg administered in single dose and
ranitidine 50 mg/kg administered in multiple doses with control groups (DMSO).
Control (n=6) Control (n=6) Control (n=6) Ranitidine 100 Control (n=6) Ranitidine 50
Hematological NaCl NaCl DMSO (n=6) DMSO (n=6)
parameters Single dose Multiple dose Single dose Single dose Multiple dose Multiple dose
mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
Erythrocytes 5.25 ± 0.27 5.30 ± 0.40 5.00 ± 0.12 5.10 ± 0.19 4.98 ± 0.37 4.95 ± 0.41
   (millions/mm³)
Hematocrit (%) 42.50 ± 1.85 46.30 ± 2.10 44.33 ± 1.21 45.50 ± 1.87 44.6 ± 1.23 43.5 ± 2.42
Hemoglobin (g/dl) 14.9 ± 1.20 14.25 ± 0.65 14.7 ± 0.80 14.51 ± 0.40 14.03 ± 1.57 13.66 ± 1.31
Mean corpuscular 28.57 ± 1.85 27.35± 0.95 29.03 ± 1.58 28.23 ± 0.48 28.11 ± 1.67 27.51 ± 1.29
   hemoglobin (pg)
Mean corpuscular 32.00 ± 1.52 30.10 ± 1.12 33.00 ± 1.09 31.57 ± 0.87 30.50 ± 1.35 29.91 ± 1.01
   hemoglobin
   concentration
   (g/dl)
Mean corpuscular 87.63 ± 1.20 88.50 ± 1.15 89.63 ± 1.41 89.43 ± 1.56 91.12 ± 1.67 90.08 ± 2.67
   volume (fl)
Reticulocytes (%) 3.25 ± 0.85 3.15 ± 1.70 3.08 ± 0.30 2.50 ± 1.22 2.89 ± 0.87 2.91 ± 0.43
Methemoglobin (%) 1.54 ± 0.13 3.95 ± 0.35 1.19 ± 0.21 5.80 ± 0.84 ** 4.22 ± 0.80 6.50 ± 0.84 **
   single dose
Ranitidine 100 mg/kg -ranitidine in single dose, Ranitidine 50 mg/kg-ranitidine in multiple dose, SD-standard deviation. **-
significance at 1% level (p<0.01).
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TABLE II - Comparison of hematological parameters (white series) for the ranitidine 100 mg/kg administered in single
dose and ranitidine 50 mg/kg administered in multiple dose with control groups (DMSO).
Control (n=6) Control (n=6) Control (n=6) Ranitidine 100 Control (n=6) Ranitidine 50
Hematological NaCl NaCl DMSO (n=6) DMSO (n=6)
parameter Single dose Multiple dose Single dose Single dose Multiple dose Multiple dose
mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
Leukocytes (mm³) 6.465 ± 1.12 7.155 ± 1.955 6.833 ± 1.07 7.320 ± 1.899 6.979 ± 989.15 8.567 ± 900.40
Neutrophil (mm3) 2.135 ± 865.25 2.578 ± 955.60 2.713 ± 996.35 2.685 ± 948.69 2.317 ± 807.15 2.243 ± 675.53
Ranitidine 100 mg/kg -ranitidine in single dose, Ranitidine 50 mg/kg-ranitidine in multiple dose, SD-standard deviation
FIGURE 1 - Effect of ranitidine on percent methemoglobin levels in the rats treated with ranitidine 100 mg/kg in single
dose and with ranitidine 50 mg/kg in multiple dose. ** p< 0.01 for the comparison between B and D with controls groups
A and C, respectively.
in the absence of other hepatic abnormalities, but is more
commonly associated with an acute hepatitis or cholestatic
reaction to the drug. However, some of these reactions are
accompanied by a generalized granulomatous reaction.
Other reported side effects have associated
ranitidine with hematological abnormalities including
granulocytopenia, thrombocytopenia and hemolytic ane-
mia. Agranulocytosis or neutropenia, although of rare
occurrence may be severe, even life-threatening. Adverse
reactions to drugs are thought to be a common cause of
neutropenia; however their study is difficult because they
are not predictable and lack of an animal fit for their study.
Autoimmune thrombocytopenia is also related to
treatment with ranitidine. The appearance of this condition
calls for the interruption of all medication given to the
patient; should this not be possible, drugs in use should be
changed. In general, platelet counts rise within 7 days, but
this effect may be delayed; patients should be handled in
a standard manner. Once a patient has demonstrated
sensitivity to the drug, its future use should be carefully
avoided.
Choo et al. (1994) demonstrated that hemolytic
anemia associated with ranitidine is of rare occurrence.
Such toxicity is uncommon, but may be exceedingly sever
leading to a rapidly fatal outcome in otherwise healthy
patients.
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The second set of adverse reactions is a predictable
intensification of the intended pharmacological response
caused by the use of high doses or overdoses of the drug.
Such reactions are in general experimentally reproducible,
and dose dependent. In the present study, in order to de-
termine hematological alterations caused by ranitidine, we
administered the drug in concentrations of 100 mg/kg
(single dose) and of 50 mg/kg (multiple doses), and
evaluated hematological parameters in the rat.
There was no significant difference in the red blood
cells series. In our study, we could find no evidence that
ranitidine induce hemolytic anemia. Only one animal
presented evidences of hemolytic crisis (not shown).
Discrete increment of leukocyte count was observed, but
differences in the white blood cells series were not
significant. The levels of methemoglobin were significantly
increased in comparison to those of control groups.
CONCLUSION
The results obtained showed that ranitidine can cau-
ses increased methemoblobinemia in the administered do-
ses, suggesting that from a certain concentration and dosage
scheme the substance can be methemeglobinemia inductor.
RESUMO
 Metemoglobinemia induzida pela ranitidina em
ratos
A idiossincrasia a fármacos é um evento adverso de
origem desconhecida, que acontece em poucas pesso-
as. É conhecido que a ranitidina, um antagonista de
receptores H2, causa reações idiossincrásicas. Para
investigar uma possível indução da ranitidina em re-
lação a hemotoxicidade, o fármaco foi administrado
intraperitonealmente (i.p.) em dois de seis grupos de
ratos machos Wistar (n=6), pesando entre 200-220 g.
O grupo I recebeu 200µL de solução salina (NaCl) por
via intraperitoneal ( i.p.), o grupo II recebeu 200µL de
NaCl durante quatro dias consecutivos, o grupo III
(controle do veículo,) recebeu 200 µL de
dimetilsulfóxido (DMSO) em dose única, o grupo IV
(controle do veículo) recebeu 200 µL de DMSO, du-
rante quatro dias consecutivos, o grupo V recebeu
100 mg/kg de ranitidina em 200 µL de DMSO em dose
única, o grupo VI recebeu 50 mg/kg de ranitidina em
200 µL de DMSO durante quatro dias consecutivos.
Realizou-se eritrograma, leucograma e determinação
da porcentagem de metemoglobina por espectro-
fotometria. A porcentagem de metemoglobinemia au-
mentou de forma significativa em ambos os grupos tra-
tados. A contagem de neutrófilos mostrou uma discre-
ta redução nos regimes de tratamento, ocasionada pro-
vavelmente pela mobilização marginal dos mesmos. No
regime de doses múltiplas, observou-se aumento no nú-
mero de leucócitos, mas seu perfil de manutenção de
distribuição permaneceu o mesmo. A ranitidina indu-
ziu a formação de metemoglobinemia nas doses admi-
nistradas, sugerindo que a partir de uma certa concen-
tração e ou esquema de dosagem, o fármaco pode ser
um indutor do processo.
UNITERMOS: Ranitidina. Metemoglobinemia. Anor-
malidades hematológicas.
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